Stoke Therapeutics Q1 2026 Results Show Progress

Stoke Therapeutics Q1 2026 Results Show Progress
Stoke Therapeutics released its first quarter 2026 financial results during an earnings call on May 7, with executives Thomas Leggett and CEO Ian Smith providing updates on the company's operational performance and strategic direction. The biotech firm, focused on developing innovative treatments, discussed key metrics including revenue generation, research and development investments, and pipeline advancement. During the call, leadership outlined the company's financial position and highlighted progress on clinical programs currently in development. Stoke's management team addressed investor concerns regarding cash burn rates, operational efficiency, and the timeline for bringing new therapies to market.